keyword
MENU ▼
Read by QxMD icon Read
search

Her2 positive, hormone positive

keyword
https://www.readbyqxmd.com/read/28427196/breast-cancer-subtypes-predict-the-preferential-site-of-distant-metastases-a-seer-based-study
#1
Qi Wu, Juanjuan Li, Shan Zhu, Juan Wu, Chuang Chen, Qian Liu, Wen Wei, Yimin Zhang, Shengrong Sun
BACKGROUND AND AIMS: This study aimed to access possible relationships between breast cancer subtypes and sites of distant metastasis in breast cancer. RESULTS: A total of 243,896 patients, including 226,451 cases in control groups were identified. Bone metastasis was found in 8848 cases, compared with 1,000 brain metastasis cases, 3434 liver metastasis cases and 4167 lung metastasis cases. Patients with all subtypes were most prone to bone metastases, the incidence of bone metastasis in HR+/HER2+ subtype was up to 5...
March 2, 2017: Oncotarget
https://www.readbyqxmd.com/read/28418889/efficacy-and-safety-of-everolimus-in-chinese-metastatic-hr-positive-her2-negative-breast-cancer-patients-a-real-world-retrospective-study
#2
Chengcheng Gong, Yannan Zhao, Biyun Wang, Xichun Hu, Zhonghua Wang, Jian Zhang, Sheng Zhang
BACKGROUND: Everolimus combined with endocrine therapy has been proved to be effective among postmenopausal women with hormone receptor-positive human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (MBC). We aimed to evaluate the efficacy and safety of everolimus plus endocrine therapy in Chinese real-world practice for the first time, and investigate factors associated with efficacy. METHODS: Seventy-five HR+/HER2- MBC patients were included in this retrospective study who received everolimus plus endocrine therapy after progression on prior endocrine therapy in Fudan University Shanghai Cancer Center (FUSCC) between June 2013 and February 2016...
March 17, 2017: Oncotarget
https://www.readbyqxmd.com/read/28417238/bilateral-mastectomy-as-overtreatment-for-breast-cancer-in-women-age-forty-years-and-younger-with-unilateral-operable-invasive-breast-cancer
#3
Cory A Donovan, Jean Bao, Alexandra Gangi, Farin Amersi, Xiao Zhang, Armando E Giuliano, Alice P Chung
BACKGROUND: Young women with breast cancer (BC) have an increased risk of contralateral breast cancer (CBC) compared with older women. This may contribute to the rising rates of bilateral mastectomy (BM), but it is unclear if BM leads to improved outcomes. METHODS: A prospectively maintained database was reviewed. Patient and tumor characteristics, survival, and rate of CBC were compared in women age ≤40 years treated for unilateral Stage 1-3 BC from January 2000 through December 2013...
April 17, 2017: Annals of Surgical Oncology
https://www.readbyqxmd.com/read/28415615/a-nation-wide-multicenter-10-year-1999-2008-retrospective-study-of-chemotherapy-in-chinese-breast-cancer-patients
#4
Qiao Li, Zhao Yang, Jinhu Fan, Jianjun He, Bin Zhang, Hongjian Yang, Xiaoming Xie, Zhonghua Tang, Hui Li, Youlin Qiao, Pin Zhang
Little information is available on the evolvement of chemotherapeutic regimens administered to Chinese females with breast cancer. We retrospectively analyzed demographic, pathological and chemotherapeutic data of 4211 breast cancer patients, who were randomly selected from representative hospitals of 7 traditional areas in China between 1999 and 2008. A total of 3271 cases (77.7%) received adjuvant chemotherapy, 558 (13.3%) received neoadjuvant chemotherapy, and 392 (9.3%) received chemotherapy for metastatic disease...
March 22, 2017: Oncotarget
https://www.readbyqxmd.com/read/28415567/efficacy-and-safety-of-t-dm1-in-the-common-practice-of-her2-advanced-breast-cancer-setting-a-multicenter-study
#5
Alessandra Fabi, Michelino De Laurentiis, Michele Caruso, Enrichetta Valle, Luca Moscetti, Daniele Santini, Katia Cannita, Luisa Carbognin, Mariangela Ciccarese, Rosalba Rossello, Grazia Arpino, Vita Leonardi, Filippo Montemurro, Nicla La Verde, Daniele Generali, Alberto Zambelli, Giuseppa Scandurra, Michelangelo Russillo, Ida Paris, Anna Maria D'Ottavio, Gianfranco Filippelli, Marianna Giampaglia, Simonetta Stani, Agnese Fabbri, Daniele Alesini, Daniela Cianniello, Diana Giannarelli, Francesco Cognetti
Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for the treatment of patients with human epidermal growth factor receptor 2 (HER2)-positive, metastatic breast cancer (mBC). The aim of this 'field-practice' study was to investigate the efficacy and safety of T-DM1, focusing on treatment line, previous lapatinib treatment and patterns of metastasis. Three hundred and three patients with HER2-positive mBC who received T-DM1 were identified by reviewing the medical records of 24 Italian Institutions...
March 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28409272/increased-trace-amine-associated-receptor-1-taar1-expression-is-associated-with-a-positive-survival-rate-in-patients-with-breast-cancer
#6
Aurelia Vattai, Elif Akyol, Christina Kuhn, Simone Hofmann, Helene Heidegger, Franz von Koch, Kerstin Hermelink, Rachel Wuerstlein, Nadia Harbeck, Doris Mayr, Christine Spitzweg, Bettina Toth, Sven Mahner, Udo Jeschke, Nina Ditsch
PURPOSE: A correlation between breast cancer and thyroid disorders has been described in previous studies. Degraded thyroid hormones are referred to as trace amines. These endogenous amines have the ability to bind to the G-protein-coupled receptor TAAR1 (trace amine-associated receptor) and thereby activate it. TAAR1 is able to modulate the serotonergic and dopaminergic system in the brain and has so far been studied in the neurological field. The following study represents the first investigation of the regulation of TAAR1 in primary breast cancer (no metastases, M0)...
April 13, 2017: Journal of Cancer Research and Clinical Oncology
https://www.readbyqxmd.com/read/28409241/mmp11-and-cd2-as-novel-prognostic-factors-in-hormone-receptor-negative-her2-positive-breast-cancer
#7
Jinil Han, Yoon-La Choi, Haein Kim, Jun Young Choi, Se Kyung Lee, Jeong Eon Lee, Joon-Seok Choi, Sarah Park, Jong-Sun Choi, Young Deug Kim, Seok Jin Nam, Byung-Ho Nam, Mi Jeong Kwon, Young Kee Shin
PURPOSE: More accurate prediction of patient outcome based on molecular subtype is required to identify patients who will benefit from specific treatments. METHODS: We selected novel 16 candidate prognostic genes, including 10 proliferation-related genes (p-genes) and 6 immune response-related genes (i-genes), from the gene list identified in our previous study. We then analyzed the association between their expression, measured by quantitative real-time reverse transcription-PCR in formalin-fixed, paraffin-embedded tissues, and clinical outcome in 819 breast cancer patients according to molecular subtype...
April 13, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28407750/adjuvant-treatment-recommendations-for-patients-with-er-positive-her2-negative-early-breast-cancer-by-swiss-tumor-boards-using-the-21-gene-recurrence-score-sakk-26-10
#8
Bernhard C Pestalozzi, Christoph Tausch, Konstantin J Dedes, Christoph Rochlitz, Stefan Zimmermann, Roger von Moos, Ralph Winterhalder, Thomas Ruhstaller, Andreas Mueller, Katharina Buser, Markus Borner, Urban Novak, Catrina Uhlmann Nussbaum, Bettina Seifert, Martin Bigler, Vincent Bize, Simona Berardi Vilei, Christoph Rageth, Stefan Aebi
BACKGROUND: To evaluate the effect of Recurrence Score® results (RS; Oncotype DX® multigene assay ODX) on treatment recommendations by Swiss multidisciplinary tumor boards (TB). METHODS: SAKK 26/10 is a multicenter, prospective cohort study of early breast cancer patients: Eligibility: R0-resection, ≥10% ER+ malignant cells, HER2-, pN0/pN1a. Patients were stratified into low-risk (LR) and non-low-risk (NLR) groups based on involved nodes (0 vs 1-3) and five additional predefined risk factors...
April 13, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28407247/using-the-21-gene-assay-from-core-needle-biopsies-to-choose-neoadjuvant-therapy-for-breast-cancer-a-multicenter-trial
#9
Harry D Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L White, James Granfortuna, Judith O Hopkins, Dwight Oldham, Angel Rodriguez, Amy P Sing
OBJECTIVE: We hypothesized that the Oncotype Dx(®) 21-gene Recurrence Score (RS) could guide neoadjuvant systemic therapy (NST) to facilitate breast conserving surgery (BCS) for hormone receptor positive (HR+) breast cancers. METHODS: This study enrolled patients with HR+, HER2-negative, invasive breast cancers not suitable for BCS (size ≥ 2 cm). Core needle biopsy blocks were tested. For tumors with RS < 11, patients received hormonal therapy (NHT); patients with RS > 25 tumors received chemotherapy (NCT); patients with RS 11-25 were randomized to NHT or NCT...
April 13, 2017: Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28399902/efficacy-and-safety-of-everolimus-in-combination-with-trastuzumab-and-paclitaxel-in-asian-patients-with-her2-advanced-breast-cancer-in-bolero-1
#10
Masakazu Toi, Zhimin Shao, Sara Hurvitz, Ling-Ming Tseng, Qingyuan Zhang, Kunwei Shen, Donggeng Liu, Jifeng Feng, Binghe Xu, Xiaojia Wang, Keun Seok Lee, Ting Ying Ng, Antonia Ridolfi, Florence Noel-Baron, Francois Ringeisen, Zefei Jiang
BACKGROUND: The current exploratory analysis was performed to evaluate the efficacy and safety of everolimus for treatment of human epidermal growth factor receptor 2-positive (HER2+) advanced breast cancer in the Asian subset of patients in the BOLERO-1 trial. METHODS: Postmenopausal women with HER2+ advanced breast cancer, who had not received systemic therapy for advanced disease, were randomized 2:1 to receive everolimus or placebo, plus trastuzumab and paclitaxel...
April 11, 2017: Breast Cancer Research: BCR
https://www.readbyqxmd.com/read/28395543/pharmacokinetic-drug-evaluation-of-ribociclib-for-the-treatment-of-metastatic-hormone-positive-breast-cancer
#11
Giuseppe Curigliano, Carmen Criscitiello, Angela Esposito, Mattia Intra, Saverio Minucci
Cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitor of CDK4/6-retinoblastoma (Rb) pathway hyperactivation is associated with hormone receptor-positive (HR+) breast cancer (BC). Ribociclib is an orally bioavailable, highly selective small molecule inhibitor of CDK4/6 that induces G1 arrest at sub-micromolar concentrations in a variety of pRb-positive cancer cells in vitro. Ribociclib is a new standard of care for metastatic HR+/HER2 negative metastatic breast cancer. Area covered: In this article, we review the preclinical and clinical development of ribociclib as well as discussing the role for novel applications of these agents outside the arena of HR-positive, HER2-negative advanced breast cancer...
April 11, 2017: Expert Opinion on Drug Metabolism & Toxicology
https://www.readbyqxmd.com/read/28382093/microrna-222-expression-as-a-predictive-marker-for-tumor-progression-in-hormone-receptor-positive-breast-cancer
#12
Song-Hee Han, Hyun Jeong Kim, Jae Moon Gwak, Mimi Kim, Yul Ri Chung, So Yeon Park
PURPOSE: The microRNA-221/222 (miR-221/222) gene cluster has been reported to be associated with the promotion of epithelial-mesenchymal transition (EMT), downregulation of estrogen receptor-α, and tamoxifen resistance in breast cancer. We studied the expression of miR-222 in human breast cancer samples to analyze its relationship with clinicopathologic features of the tumor, including estrogen receptor status, expression of EMT markers, and clinical outcomes. METHODS: Quantitative real-time polymerase chain reaction was performed to detect the expression of miR-222 in 197 invasive breast cancers...
March 2017: Journal of Breast Cancer
https://www.readbyqxmd.com/read/28378298/differential-impact-of-hormone-receptor-status-on-survival-and-recurrence-for-her2-receptor-positive-breast-cancers-treated-with-trastuzumab
#13
Andrew McGuire, Olga Kalinina, Emma Holian, Catherine Curran, Carmel A Malone, Ray McLaughlin, Aoife Lowery, James A L Brown, Michael J Kerin
INTRODUCTION: Hormone receptor status has major implications for treatment and survival of breast cancer. Yet the impact of hormone receptor status on outcome after Trastuzumab has received little attention. The objective here was to explore any differential effects of Trastuzumab treatment (Trast +ve) on Luminal B HER2 or HER2+(ER-) breast cancer subtypes. METHODS: A cohort of 469 HER2 receptor-positive breast cancers was categorised by molecular subtype and Trastuzumab treatment...
April 4, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28377466/complete-metabolic-response-on-interim-18-f-fluorodeoxyglucose-positron-emission-tomography-computed-tomography-to-predict-long-term-survival-in-patients-with-breast-cancer-undergoing-neoadjuvant-chemotherapy
#14
Suyun Chen, Nuhad K Ibrahim, Yuanqing Yan, Stephen T Wong, Hui Wang, Franklin C Wong
BACKGROUND: This study aims to investigate the prognostic role of complete metabolic response (CMR) on interim (18)F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) in patients with breast cancer (BC) receiving neoadjuvant chemotherapy (NAC) according to tumor subtypes and PET timing. PATIENTS AND METHODS: Eighty-six consecutive patients with stage II/III BC who received PET/CT during or following NAC were included. Time-dependent receiver operating characteristic analysis and Kaplan-Meier analysis were used to determine correlation between metabolic parameters and survival outcomes...
April 4, 2017: Oncologist
https://www.readbyqxmd.com/read/28376188/regional-nodal-irradiation-after-breast-conserving-surgery-for-early-her2-positive-breast-cancer-results-of-a-subanalysis-from-the-altto-trial
#15
Isabelle Gingras, Eileen Holmes, Evandro De Azambuja, David H A Nguyen, Miguel Izquierdo, Jo Anne Zujewski, Moshe Inbar, Bjorn Naume, Gianluca Tomasello, Julie R Gralow, Antonio C Wolff, Lyndsay Harris, Michael Gnant, Alvaro Moreno-Aspitia, Martine J Piccart, Hatem A Azim
Background: Two randomized trials recently demonstrated that regional nodal irradiation (RNI) could reduce the risk of recurrence in early breast cancer; however, these trials were conducted in the pretrastuzumab era. Whether these results are applicable to human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients treated with anti-HER2-targeted therapy is unknown. Methods: This retrospective analysis was performed on patients with node-positive breast cancer who were enrolled in the Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization phase III adjuvant trial and subjected to BCS...
August 1, 2017: Journal of the National Cancer Institute
https://www.readbyqxmd.com/read/28375706/impact-of-diabetes-insulin-and-metformin-use-on-the-outcome-of-patients-with-human-epidermal-growth-factor-receptor-2-positive-primary-breast-cancer-analysis-from-the-altto-phase-iii-randomized-trial
#16
Amir Sonnenblick, Dominique Agbor-Tarh, Ian Bradbury, Serena Di Cosimo, Hatem A Azim, Debora Fumagalli, Severine Sarp, Antonio C Wolff, Michael Andersson, Judith Kroep, Tanja Cufer, Sergio D Simon, Pamela Salman, Masakazu Toi, Lyndsay Harris, Julie Gralow, Maccon Keane, Alvaro Moreno-Aspitia, Martine Piccart-Gebhart, Evandro de Azambuja
Purpose Previous studies have suggested an association between metformin use and improved outcome in patients with diabetes and breast cancer. In the current study, we aimed to explore this association in human epidermal growth factor receptor 2 (HER2 ) -positive primary breast cancer in the context of a large, phase III adjuvant trial. Patients and Methods The ALTTO trial randomly assigned patients with HER2-positive breast cancer to receive 1 year of either trastuzumab alone, lapatinib alone, their sequence, or their combination...
March 13, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28373182/energy-balance-modulation-impacts-epigenetic-reprogramming-er%C3%AE-and-er%C3%AE-expression-and-mammary-tumor-development-in-mmtv-neu-transgenic-mice
#17
Emily L Rossi, Sarah M Dunlap, Laura W Bowers, Subreen A Khatib, Steven S Doerstling, Laura A Smith, Manu A Sharma, Darcy Holley, Powel H Brown, Marcos R Estecio, Donna F Kusewitt, Linda A deGraffenried, Scott J Bultman, Stephen D Hursting
The association between obesity and breast cancer risk and prognosis is well established in ER-positive disease but less clear in HER2-positive disease. Here, we report preclinical evidence suggesting weight maintenance through calorie restriction may limit risk of HER2-positive breast cancer. In female MMTV-HER2/neu transgenic mice, we found that ERα and ERβ expression, mammary tumorigenesis and survival are energy balance-dependent in association with epigenetic reprogramming. Mice were randomized to receive a calorie restriction (CR), overweight (OW)-inducing, or diet-induced obesity (DIO) regimen (n = 27/group)...
April 3, 2017: Cancer Research
https://www.readbyqxmd.com/read/28371729/impact-of-adjuvant-chemotherapy-on-survival-of-women-with-t1n0m0-hormone-receptor-negative-breast-cancer
#18
Nanthini Thevi Bhoo-Pathy, Shinako Inaida, Shiro Tanaka, Nur Aishah Taib, Cheng-Har Yip, Marniza Saad, Koji Kawakami, Nirmala Bhoo-Pathy
BACKGROUND: The benefit of adjuvant chemotherapy in women with T1N0M0 breast cancers is unclear. While gene expression-based prognostic assays may aid management of women with early estrogen receptor (ER) positive tumors, therapeutic decision-making in women with early stage ER negative tumors remains fraught with difficulties. We investigated the association between adjuvant chemotherapy and overall survival in women with T1N0M0, hormone receptor negative breast cancers. METHOD: All newly diagnosed breast cancer patients with node-negative and hormone receptor negative tumors measuring≤2cm at the University Malaya Medical Centre (Malaysia) from 1993 to 2013 were included...
March 31, 2017: Cancer Epidemiology
https://www.readbyqxmd.com/read/28365833/estrogen-and-progesterone-receptor-expression-levels-do-not-differ-between-lobular-and-ductal-carcinoma-in-patients-with-hormone-receptor-positive-tumors
#19
Wilfred Truin, Rudi M H Roumen, Sabine Siesling, Koen K van de Vijver, Vivianne C G Tjan-Heijnen, Adri C Voogd
BACKGROUND: Differences in estrogen (ER) and progesterone (PR) expression between invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) could be an underlying reason for the difference in chemo-sensitivity and response to hormonal therapy between ILC and IDC. The aim of this study was to investigate the differences in ER and PR expression levels between postmenopausal patients with hormonal receptor-positive ILC and IDC. METHODS: We included all ER and/or PR receptor-positive ILC and IDC, diagnosed between January 2011 and December 2013 from the population-based Netherlands Cancer Registry...
April 1, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28359319/endocrine-therapy-initiation-discontinuation-and-adherence-and-breast-imaging-among-21-gene-recurrence-score-assay-eligible-women-under-age-65
#20
Suzanne C O'Neill, Claudine Isaacs, Filipa Lynce, Deena Mary Atieh Graham, Calvin Chao, Vanessa B Sheppard, Yingjun Zhou, Chunfu Liu, Nandini Selvam, Marc D Schwartz, Arnold L Potosky
BACKGROUND: Aside from chemotherapy utilization, limited data are available on the relationship between gene expression profiling (GEP) testing and breast cancer care. We assessed the relationship between GEP testing and additional variables and the outcomes of endocrine therapy initiation, discontinuation and adherence, and breast imaging exams in women under age 65 years. METHODS: Data from five state cancer registries were linked with claims data and GEP results...
March 31, 2017: Breast Cancer Research: BCR
keyword
keyword
21972
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"